Close
Smartlab Europe
Inizio Ignite

Industry Reports

Stable consolidated revenues, costs and losses for Hybrigenics

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in protein interactions, today presents its consolidated accounts for the first half...

Hikma Pharma Q1 revenue rises

Hikma Pharmaceuticals, a manufacturer of a range of both branded and non-branded generic and inlicensed products, reported revenue of $394.76m for the first quarter ended 30 June 2011, compared to $357.69m for the same period in 2010. ...

Furiex Pharmaceuticals Enters into Loan Agreement for up to $15 Million Furiex Pharmaceuticals Inc.

Furiex Pharmaceuticals, Inc. announced it has entered into a loan agreement with MidCap Financial and Silicon Valley Bank to provide up to $15.0 million in capital through a secured term loan. Furiex intends to use the proceeds to support...

China Shenghuo Q2 sales climb 58%

China Shenghuo, engaged in the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products, has reported sales of $10.9m for the second quarter ended 30 June 2011, an increase of 58% compared to...

Vivus reports Qnexa phase 3 study results

Vivus, a developer of therapies to address obesity, sleep apnea, diabetes and male sexual health, has reported the data of Qnexa in its Phase 3 study.Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase...

Novartis delivers strong financial results and four major approvals

Novartis' net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by 8% as the US dollar weakened against most currencies. Recently launched products grew 46% over the previous-year quarter, contributing USD 3.8 billion to total...

Echo Therapeutics Announces First Quarter 2011 Financial Results

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced results for the period ended March...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »